Company news

Hyloris Pharmaceuticals SA news in 2025

Hyloris Pharmaceuticals SA's news releases, calls and decks from 2025, newest first.

View company

Licenses European and Turkish Rights to Next-Generation Wilson’s Disease Candidate from ArborMed

December 30, 2025

Hyloris Pharmaceuticals: Inside Information Hyloris Announces Partnership with Rosemont Pharmaceuticals for Atomoxetine Oral Solution in the U.S. ENGLISH VERSION

December 29, 2025

Hyloris Pharmaceuticals Receives Exclusive License Option for Innovative Topical Therapy for a Rare Genetic Skin Disorder

December 11, 2025

Hyloris Pharmaceuticals: Board of Directors appoints Stijn Van Rompay as CEO

November 19, 2025

Hyloris Pharmaceuticals Announces Positive Clinical Study Results for IV Aspirin

November 14, 2025

Inside Information Hyloris and Orion Partner to Bring Tranexamic Acid RTU to Key European Markets ENGLISH VERSION

October 28, 2025

Hyloris Pharmaceuticals Announces Partnership with Grand Life Sciences Group for HY-094 in China

October 27, 2025

Consolidated 2025 Half-Year Results and Outlook: Hyloris Achieves Strong Royalty Growth and Portfolio Expansion with Solid Cash Position

September 25, 2025

Decks in 2025